Folic acid prevents 70 percent of human neural tube defects (NTDs) but its mode of action is unclear. The deoxyuridine suppression test detects disturbance of folate metabolism in homozygous splotch (Pax3) mouse embryos that are developing NTDs in vitro. Excessive incorporation of [ 3 H]thymidine in splotch embryos indicates a metabolic deficiency in the supply of folate for the biosynthesis of pyrimidine. Exogenous folic acid and thymidine both correct the biosynthetic defect and prevent some NTDs in splotch homozygotes, whereas methionine has an exacerbating effect. These data support a direct normalization of neurulation by folic acid in humans and suggest a metabolic basis for folate action.
Up to 70% of human NTDs, including anencephaly and spina bifida, can be prevented when folic acid-containing vitamin preparations, or folic acid alone, are administered in the periconceptual period (1) . Despite the importance of this primary health-care measure, the mechanism by which folic acid exerts its preventive effect is unknown. Folic acid seems likely to promote normal development, although it could cause early spontaneous abortion of fetuses with NTD (2) .
Mothers of human fetuses with NTDs have either normal or, at most, mildly deficient folate status (3), which argues against an etiology of NTD based on maternal folate deficiency. Supporting this argument is the finding that folic acid deficiency does not cause NTDs in mice or in cultured rat embryos (4) . Disregulated methionine synthase could promote NTDs, because folate and vitamin B 12 concentrations are independent risk factors for NTDs, and homocysteine concentrations are mildly increased in maternal blood and amniotic fluid of NTD pregnancies (5) . However, genetic association between the methionine synthase gene and NTDs in affected families remains obscure (6) , and inhibition of methionine synthase in rats does not produce NTD (7) . The enzyme 5,10-methylene tetrahydrofolate reductase (MTHFR) has also been implicated in the etiology of NTD (8) , although this idea remains controversial (9) .
Here, we identify a mouse model of folate-preventable NTD that indicates how embryonic folate metabolism may be disturbed. We adapted the deoxyuridine (dU) suppression test, used previously to detect altered folate metabolism in megaloblastic anemias (10) . Deoxythymidine monophosphate (dTMP) can be synthesized either from deoxyuridine monophosphate (dUMP), through the action of thymidylate synthase, or from thymidine, via the salvage pathway catalyzed by thymidine kinase (Fig.  1A ). In the dU suppression test, incorporation of [ 3 H]thymidine into dTMP, and thence into DNA, is suppressed by exogenous dUMP. Suppression occurs when folate metabolism is unimpaired, whereas thymidine incorporation is suppressed less by dUMP when folate cycling is compromised.
Embryonic day 8.5 (E8.5) mouse embryos growing in culture for 24 hours exhibit a dose-dependent suppression of [ 3 H]thymidine incorporation by dUMP (Fig. 1B) ; the suppression is significantly diminished, however, in the presence of antimetabolites that inhibit folate and methionine cycling (11), including aminopterin, 5-fluorouracil, or cycloleucine (Fig. 1C) . Embryos cultured in folate-deficient serum (12) show normal suppression in response to dUMP (Fig. 1C) , indicating that they have sufficient folate reserves to support neurulation.
Mouse embryos homozygous for the curly tail and loop-tail mutations, which develop spina bifida and craniorachischisis, respectively, show dU suppression (13) that does not differ significantly from that of wildtype embryos (Fig. 1D) . In contrast, dU suppression is abnormal in embryos homozygous for the mutation splotch (Sp 2H ), which develop anencephaly and spina bifida (Fig. 1D) Fig.  2A ), whereas addition of methionine exacerbates the difference (P Ͻ 0.001; Fig. 2B and heterozygotes is indistinguishable from that of wild type (Fig. 2C) .
To test whether NTDs in splotch embryos can be prevented, we added folic acid, thymidine, dUMP, methionine, or PBS to embryo cultures (14). Among Sp 2H homozygotes cultured from E8.5 to E10.5, folic acid and thymidine were protective (Fig. 3) , whereas methionine increased the incidence of NTDs to 47% (21 of 44) among splotch heterozygotes, which ordinarily do not develop NTDs. Folic acid and thymidine also prevented some NTDs when delivered in utero to splotch embryos (15) (Fig.  3A) . Thus, exogenous folic acid can prevent the development of NTDs by normalizing the neurulation process in genetically predisposed mouse embryos. This finding strengthens the argument for primary prevention of human NTDs by folic acid and suggests that folic acid is unlikely to cause the abortion of affected fetuses (2) .
The excess incorporation of [ 3 H]thymidine by splotch embryos, and the correction of this defect by exogenous folic acid, indicate that the supply of 5,10-methylene tetrahydrofolate (MTHF) for de novo pyrimidine biosynthesis in splotch is inadequate. Because both folic acid and thymidine can prevent NTDs in splotch embryos, this abnormality of pyrimidine biosynthesis may be functionally important in preventing closure of the neural tube. The exacerbating effect of methionine on NTDs is unclear but could result from excess accumulation of homocysteine, which produces NTDs in chick embryos but not in the rat (16) . Alternatively, methionine treatment could increase the concentrations of Sadenosylhomocysteine, which can derepress MTHFR (17) and potentially exacerbate the shortage of MTHF.
Cranial NTDs resulting from a null mutation of the Cart1 homeobox gene are also preventable by folic acid, whereas spinal NTDs in the Axial defects mutant appear susceptible to methionine treatment but not to folic acid or vitamin B 12 (18) . It will be interesting to determine whether these mutants exhibit an underlying defect of folate metabolism. The curly tail and loop-tail mutants, both of which develop NTDs, yield normal responses to dU suppression, suggesting that folate metabolism is not deranged in either mutant. Indeed, NTDs in the curly tail mouse are resistant to treatment with folic acid (19) , although myo-inositol, which acts through a biochemical pathway unrelated to folic acid, is able to prevent a large proportion of the NTDs in curly tail mice (20) . Thus, mouse NTDs, and probably human NTDs as well (21) , are heterogeneous in their molecular pathogenesis.
The Pax3 gene is mutated in splotch mice (22) , and the Pax3 transcription factor may regulate genes such as N-CAM, N-cadherin, c-met, MyoD, Myf-5 and versican (23) . Pax3 is expressed in the closing neural folds and adjacent tissues (24) ; whether expression of folate metabolic enzymes is controlled at these sites by Pax3 has yet to be determined. Humans with Waardenburg syndrome types I and III have mutations in PAX3, with a particular prevalence of NTDs in homozygotes (25) . Although PAX3 mutations do not appear to cause the majority of familial NTDs in humans (25) , misregulation of embryonic PAX3 expression could be involved in some cases of human NTD. Our study suggests that thymidine therapy could serve as an adjunct to folic acid supplementation to prevent human NTDs, whereas methionine treatment is contraindicated. SCIENCE ⅐ VOL. 280 ⅐ 26 JUNE 1998 ⅐ www.sciencemag.org lyzed for [ 3 H]thymidine incorporation into DNA and for total protein content (bicinchoninic acid protein assay; Pierce). We performed the experiment on nine occasions, with n ϭ 3 embryos per concentration. 11. To test antimetabolites, the dU suppression tests were performed with CD1 embryos, cultured in the presence of aminopterin (1 mg/ml), 5-fluorouracil (2 mg/ml), or cycloleucine (2 mg/ml) (minimum teratogenic doses established in preliminary studies). These experiments were performed on two to four occasions, with n ϭ 3 embryos per group. 12. CD1 embryos were cultured from E8.5 to E9.5 in folate-deficient serum prepared by extensive dialysis of rat serum as described (20, 26) with addition of myo-inositol (10 g/ml). Folic acid (1.0 mg/ml) was added to the control cultures. The experiment was performed on three occasions, with n ϭ 6 embryos per group. 13. CD1 random-bred mice (Charles River, UK) served as nonmutant controls. Mutant mice were splotch (Sp 2H ), loop-tail (Lp/ϩ), and curly tail (ct). The Sp
2H
allele was maintained on a mixed C3H/He, 101, and CBA/Ca background. Litters from heterozygote matings were genotyped by using a Pax3-specific polymerase chain reaction (PCR) (22) . Lp/ϩ mice were produced by mating congenic LPT/Le congenic males with inbred CBA/Ca females (Harlan Olac, UK). Litters from heterozygote matings were genotyped by Crp PCR (27) . All curly tail individuals were homozygous ct/ct, of which 45 to 55% exhibited tail defects or open spinal NTDs. Embryos were categorized as affected or unaffected on the basis of posterior neuropore length at the 27-to 29-somite stage (28) . The dU suppression tests were performed on mutant embryos on four to seven occasions, with n ϭ 3 to 6 embryos per group. Animal care was in accordance with UK governmental legislation (project licence 80/00503). 14. Splotch and CD1 embryos were cultured from E8. 5 to E10.5 in the continuous presence of folic acid (200 g/ml), thymidine (250 g/ml), dUMP (500 M), or methionine (1.5 mg/ml) (maximum nonteratogenic doses established in preliminary studies). 15. Pregnant splotch heterozygotes were injected intraperitoneally on E8.5 and E9.5 with folic acid or thymidine (each at 10 mg/kg body weight) or with an equivalent volume of PBS. Litters were collected at E12.5 or E13. G proteins transduce signals from a large number of cell surface heptahelical receptors to various intracellular effectors, including adenylyl cyclases, phospholipases, and ion channels. Each heterotrimeric G protein is composed of a guanine nucleotide-binding ␣ subunit and a high-affinity dimer of ␤ and ␥ subunits. G␣ subunits are commonly grouped into four subfamilies (G s , G i , G q , and G 12 ) on the basis of their amino acid sequences and function (1) . The G 12 subfamily has only two members, ␣ 12 and ␣ 13 (2) . G␣ 12 and G␣ 13 participate in cell transformation and embryonic development, but the signaling pathways that are regulated by these proteins have not been identified (3). However, the small GTPase Rho mediates the formation of actin stress fibers and the assembly of focal adhesion complexes induced by the expression of constitutively active forms of G␣ 12 or G␣ 13 (4) . Members of the RGS family of proteins negatively regulate G protein signaling (5) . The family includes at least 19 members in mammals and is defined by a core domain called the RGS box. Several RGS proteins act as GTPase activating proteins (GAPs) for ␣ subunits in the G i or G q subfamilies (6, 7). The crystal structure of a complex between RGS4 and AlF 4 --activated G␣ i1 revealed that the functional core of RGS4 (the RGS box), which is sufficient for GAP activity (8) , contains nine ␣ helices that fold into two small subdomains (9) . The residues of the box that form its hydrophobic core are conserved, and they are important for the stability of structure and GAP activity (9, 10) . RGS4 stimulates the GTPase activity of G␣ i1 predominantly by interacting with its three mobile switch regions, thereby stabilizing the transition state for GTP hydrolysis (9, 11) .
The activities of members of the Rho family of monomeric GTPases are regulated by guanine nucleotide exchange factors (GEFs) that contain a dbl homology (DH) domain (12). Examination of the sequence of p115 (13), a GEF specific for Rho, reveals an NH 2 -terminal region with similarity to the conserved domain of RGS proteins (Fig. 1) . Most of the hydrophobic residues that form the core of this domain (17 of 23) are conserved in p115 RhoGEF. The positions of breaks in the alignment correspond to the loops between ␣ helices in the RGS domain structure. This suggests that p115 RhoGEF may have a similar structural domain and GAP activity. However, the residues of RGS4 that make contact with the switch regions of G␣ i1 -GDPAlF 4 -(GDP, guanosine diphosphate) are not well conserved in p115 RhoGEF, sug-
